A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

PHASE4

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Due to rare patient population, planned number of patients could not be recruited in a reasonable timeframe. Recruitment was stopped prematurely.

Conditions

Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women

Interventions

DRUG: Zoledronic Acid
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals